International application No. PCT/SE 2004/000452

## A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 31/439, A61K 31/52, A61K 31/4015, A61P 35/00 According to International Patent Classification (IPC) or to both national classification and IPC

### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

#### IPC7: A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

## SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

## CHEM. ABS DATA, BIOSIS, EMBASE, MEDLINE, EPO-INTERNAL

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
A	WO 0224692 A1 (KAROLINSKA INNOVATIONS AB), 28 March 2002 (28.03.2002)	1-11	
	<del>,</del>		
A	J. Clin. Invest., Vol. 98, no. 2, July 1996, Staffan Strömblad et al: "Suppression of p53 Activity and p21WAF1/CIP1 Expression by Vascular Cell Integrin alpha v beta 3 during Angiogenesis", page 426 - page 433	1-11	
	<del>-</del>		
A	The Journal of Biological Chemistry, Vol. 277, no. 16, 19 April 2002, Staffan Strömblad et al: "Loss of p53 Compensates for alpha v-Integrin Function in Retinal Neovascularization", page 13371 - page 13374	1-11	

X	Further documents are listed in the continuation of Box C. X See patent family annex.				
*	Special categories of cited documents:	"T"	later document published after the international filing date or priority		
"A"	document defining the general state of the art which is not considered to be of particular relevance		date and not in conflict with the application but cited to understand the principle or theory underlying the invention		
"E"	earlier application or patent but published on or after the international filing date		considered novel or cannot be considered to involve an inventive		
"L"			step when the document is taken alone		
			document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is		
"O"	document referring to an oral disclosure, use, exhibition or other means		combined with one or more other such documents, such combinate being obvious to a person skilled in the art		
"P"	document published prior to the international filing date but later than the priority date claimed	*&*	document member of the same patent family		
Date	Date of the actual completion of the international search		Date of mailing of the international search report		
	29 June 2004		0 2 -07- 2004		
Nan	Name and mailing address of the ISA/		Authorized officer		
	Swedish Patent Office				
	Box 5055, S-102 42 STOCKHOLM Facsimile No. + 46 8 666 02 86		Per Renström/BS Telephone No. +46 8 782 25 00		

International application No.
PCT/SE 2004/000452

	· 1	
C (Continu	ation). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passage	Relevant to claim No
A	Carcinogenesis, Vol. 23, no. 12, 2002, Vladimir J.N. Bykov et al: "Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database", page 2011 - page 2018	1-11
A	Nature Medicine, Vol. 8, no. 3, March 2002, Vladimir J.N. Bykov et al: "Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weightcompound", page 282 - page 28	1-11
P,X	WO 03070250 A1 (KAROLINSKA INNOVATIONS AB), 28 August 2003 (28.08.2003)	1-11
į		
L	SA/210 (continuation of second sheet) (January 2004)	

International application No. PCT/SE 2004/000452

Box N	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)	
This in	national search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:	
1. 🔀	Claims Nos.: 5 because they relate to subject matter not required to be searched by this Authority, namely: see extra sheet	
2. <u>~</u>	Claims Nos.: 1, 4-5 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  see extra sheet	
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box N	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)	4
This I	rnational Searching Authority found multiple inventions in this international application, as follows:	
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.	- 1
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment any additional fee.	of
3. [	As only some of the required additional search fees were timely paid by the applicant, this international search report cover only those claims for which fees were paid, specifically claims Nos.:	S
4. [	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	
Rem	The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.	

International application No. PCT/SE 2004/000452

#### Box II.1

Claim 5 relates to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practiced on the human or animal body (Rule 39.1(iv)). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compounds or compositions.

#### Box II.2

Present claims 1 and 4-5 relate to an extremely large number of possible compounds. Support within the meaning of Article 6 PCT and / or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds for which pharmaceutical use is claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts related to the compounds in claims 2-3, except for the parts related to the expression "prodrug" (see below).

The scope of claims 1-2 and 4-5, as far as the expression "prodrug" is concerned, is so unclear (Article 6 PCT) that a meaningful search is impossible with regard to this expression.

# INTERNATIONAL SEARCH REPORT Information on patent family members

30/04/2004

International application No. PCT/SE 2004/000452

MO	0224692	A1	28/03/2002	AU CA EP US	9042201 A 2423192 A 1319000 A 2003166674 A	02/04/2002 28/03/2002 18/06/2003 04/09/2003
MO	03070250	A1	.28/08/2003	EP SE	1377334 A 0200523 D	07/01/2004 00/00/0000

Form PCT/ISA/210 (patent family annex) (January 2004)